Memory Pharma IPO Proceeds Will Fund Phase II Alzheimer’s Studies
Executive Summary
Memory Pharmaceuticals will use the proceeds from its initial public offering to fund Phase II trials for two Alzheimer's disease agents
You may also be interested in...
Genitope IPO Would Fund Phase III Cancer Vaccine Trials
Genitope plans to use proceeds from an initial public offering to fund enrollment of 360 patients in a pivotal study of the MyVax therapeutic cancer vaccine
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials